BoYin Biotech Secures Tens of Millions in Angel+ Funding to Advance Non-Viral Vector Gene Therapies, WinX Capital Acts as Exclusive Financial Advisor

Recently,Shanghai Boyin BiotechnologyCo., Ltd. (“BoYin Bio”or“Company”) Completed tens of millions of yuan in angel+round of financing. This round of investment was led by the Zhangjiang Life and Health Industry Incubation Angel Fund (“Zhang Ke Hemiao Fund” led the investment,Existing Shareholder: FreeS FundCapitalWith continued additional investment from the founders, WinX Capital served as the exclusive financial advisor for this round。The funds raised will be primarily used to advance the company’s product pipeline and conduct early-stage clinical validation of its first product, while also supporting the iteration of the company’s technology platform to provide a source of innovation for its sustainable future development.

Boyin BioDr. Pan Yukun, CEO, said“Born out of the Zhangjiang Pharma Valley platform, Boyin Biologics has thrived under Zhangjiang’s high-quality incubation system since its establishment. The company has built a globally leading nucleic acid preparation and in vivo delivery technology platform based on non-terminal DNA (neDNA) with independent intellectual property rights, and has established multiple innovative product pipelines for non-viral vector gene therapies. The global gene therapy market is currently undergoing a transformation, with product development shifting from being driven by scientific technology and clinical validation to being driven by products and market demand, bringing along new opportunities and challenges. Adhering to fundamental innovation, Boyin Biologics is committed to developing low-cost, repeatable-dosing gene therapy products. In response to current market changes, the company is actively laying out product pipelines for common diseases such as sarcopenia and bladder cancer, leveraging its technological platform advantages to develop best-in-class, or even first-in-class, products. Amidst the overall challenges facing the global innovative drug industry, the successful completion of this financing round, supported by both existing and new shareholders against the trend, holds significant importance for the company. Looking ahead, Boyin Biologics will accelerate the development of Gene Therapy 2.0 drugs to benefit patients worldwide at an earlier date.”

BoYin Biologics was co-founded by Yale-educated returnee PhDs with global perspectives and local entrepreneurial experience, together with senior scientists in domestic gene therapy translational research. The company is primarily engaged in the development of non-viral vector gene therapies, focusing on addressing three major pain points in the field: vector capacity limitations, inability to administer repeat doses, and high production costs, thereby contributing to the global Gene Therapy 2.0 revolution. BoYin Biologics has established three core technology platforms: end-free DNA preparation, LNP-based in vivo cell-type-specific targeted delivery, and in vivo electroporation/mechanotransfection delivery, and has secured comprehensive intellectual property protection both domestically and internationally. The company strategically focuses on delivery to the liver, eyes, muscles, bladder, and blood cells, aiming to provide breakthrough therapies for patients with genetic disorders and major chronic diseases. Its product pipeline includes treatments for sarcopenia, bladder cancer, and hemophilia A. In its early stages, the company was selected for the Merck China Accelerator, received key support from the Ministry of Human Resources and Social Security’s Program for Supporting Returning Overseas Chinese Entrepreneurs, and was recognized as one of KPMG China’s Top 50 Biotech Innovation Enterprises.

The Zhang Ke He Miao Fund, with Zhangjiang Group (Zhangjiang Sci-Tech Investment) as its cornerstone investor, represents a significant initiative by Zhangjiang Sci-Tech Investment to deeply integrate “incubation + investment.” By focusing on “early-stage, small-scale, and innovative” investments, the fund guides industrial development directions, helps Zhangjiang Sci-Tech Investment build a full-chain accelerated sci-tech innovation service system, addresses capital gaps in the stage of achievement transformation, establishes a closed-loop synergy between incubation and investment, and channels “patient capital” into seed-stage and start-up technology enterprises.

WinX Capital is a leading investment bank in China’s healthcare and wellness industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in the Healthcare Sector for 2024,” Diyixinsheng’s “No. 1 Financial Advisory Firm in the Healthcare Sector for 2022–2024,” and VCBeat’s “Annual Healthcare Financial Advisor among the Future Healthcare 100 for 2022–2024.”